Device Trial Radar · NCT06966427
Prospective Evaluation of a Dose Guidance System for People With Diabetes Initiating Basal Insulin or Using Insulin Injections
Last checked: Nov 19, 2026Latest source record: May 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
May 8, 2025
Primary completion
May 25, 2026
Study completion May 25, 2026
Sponsor
- Lead sponsor
- Rabin Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- DreaMed Diabetes
- First posted
- May 11, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 6 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A prospective, randomized, single blind, two-arms, multicenter study. The study aims to assess the safety of a dosing-guided system (DGS) that provides direct advice on insulin dosing recommendations and diabetes management to individuals with diabetes using insulin or starting basal insulin therapy, guided by their continuous glucose monitoring (CGM). The study population will include up to 45 individuals with diabetes, distributed as follows: 15 with Type 1 diabetes (T1D) and 15 with Type 2 diabetes (T2D), both on MDI therapy and 15 with T2D using or starting to use basal insulin. The study will include a 2- to 4-week run-in period followed by a 6-week intervention period.
Conditions
- Type 1 Diabetes
- Type 2 Diabetes
Interventions
Dosing Guidance System to be used with both time and amount of insulin as inputDevice
Any insulin dosing event manually logged by the participant, the DGS will receive the time and amount of the dose as input
Dosing Guidance System to be used with only time of insulin as inputDevice
any insulin dosing event manually logged by the participant, the DGS will receive only the time of the dose as input
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sensor glucose percentage of time in hypoglycemia below 54 mg/dLTime frame: Aafter 6 weeks of intervention period
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Schneider Children Medical Center of Israel
Petah Tikva, Israel · Not yet recruiting
University Medical Center of Ljubljana
Ljubljana, Slovenia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.